The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes.
OBJECTIVE
To investigate the effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival human leukocyte antigen II (HLA-DR) expression in dry eyes.


METHODS
Sixty patients with dry eyes were randomized to 2 groups. Patients in group 1 received topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%; and patients in group 2 received sodium hyaluronate without pranoprofen. Ocular surface disease index (OSDI), tear &filig;lm break-up time (TBUT), Schirmer I test, ocular surface staining (OSS), and conjunctival HLA-DR expression were evaluated before treatment and at 15 and 30 days after treatment.


RESULTS
On day 15, patients in group 1 had significantly lower OSDI, OSS, and HLA-DR-positive cells compared with patients in group 2 (P < 0.01), and the TBUT was significantly longer in patients in group 1 than that of patients in group 2 (P < 0.01). On day 30, the difference between the 2 groups in OSS lost significance; however, there continued to be significant differences in the OSDI, TBUT, and HLA-DR expression between the 2 groups (P < 0.01). On days 15 and 30, the values in group 1 patients had significant improvement compared with their baseline values in terms of the above-mentioned parameters. The comparisons within group 2 did not reveal any significant differences. There was no significant effect in the Schirmer I test value in eyes of patients in group 1 or group 2 at days 15 or 30 (P > 0.05).


CONCLUSIONS
Topical pranoprofen 0.1% has a beneficial effect in reducing the ocular signs and symptoms of dry eyes and decreasing the inflammatory markers of conjunctival epithelial cells.
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Xiaowei
X
Liu
Shuran
S
Wang
Andrew A
AA
Kao
Qin
Q
Long
D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001578:Benzopyrans / Q000008:administration & dosage*; D003228:Conjunctiva / Q000187:drug effects* / Q000378:metabolism; D004338:Drug Combinations; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006684:HLA-DR Antigens / Q000378:metabolism*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D008297:Male; D009883:Ophthalmic Solutions; D011422:Propionates / Q000008:administration & dosage*; D011446:Prospective Studies; D013666:Tears / Q000737:chemistry; D055675:Viscosupplements / Q000008:administration & dosage
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001578:Benzopyrans; D004338:Drug Combinations; D006684:HLA-DR Antigens; D009883:Ophthalmic Solutions; D011422:Propionates; D055675:Viscosupplements; C043940:pyranoprofen; D006820:Hyaluronic Acid